The rationale begins with the design of modern antibiotics. Most act on one principal molecular target, whether cell-wall synthesis, protein synthesis, nucleic-acid synthesis, folate metabolism or membrane function. That specificity creates a corresponding escape route: bacteria can alter the target, increase drug efflux, enzymatically inactivate the compound or protect the target with dedicated proteins. A single mutation or acquired resistance mechanism may therefore be enough to blunt the drug. By contrast, the review notes, bacterial resistance can also spread through mobile genetic elements, allowing resistant genes to move between related and unrelated species. A strategy aimed at several conserved targets would not make resistance impossible, but it would require bacteria to overcome several pressures simultaneously rather than relying on one successful adaptation.

Ayurvedic antibacterial preparations are presented in this context as naturally occurring polypharmacological mixtures. Their activity is attributed not to one plant-specific constituent but to recurring classes of secondary metabolites, including flavonoids, tannins, saponins, phenolic acids and terpenoids. These compounds converge on features shared by many bacteria, including the cell envelope and enzymes needed for replication and metabolism. The review cites serial-passage evidence in which Staphylococcus aureus, Acinetobacter baumannii and Pseudomonas aeruginosa evolved resistance less readily against a historical multi-component antimicrobial than against single-target controls. This observation supports the general logic of multi-target pressure, although it does not establish that any particular Ayurvedic preparation will behave similarly in patients.

The review focused on peer-reviewed studies retrieved from Google Scholar, PubMed and Scopus, using terms that included “antimicrobial resistance,” “Ayurveda,” “polypharmacology,” “antibiotic adjuvants,” “phytochemicals” and “multi-target mechanism.” Calotropis procera, Azadirachta indica, Ocimum sanctum, the Acacia genus and Asparagus racemosus were selected for detailed treatment because they were frequently cited in the surveyed literature and had comparatively well-characterized mechanisms; this was a qualitative judgment rather than a numerical threshold. Studies reporting stand-alone antibacterial effects without mechanistic detail, non-peer-reviewed work and studies of non-human pathogens were excluded. The authors generated no new experimental, in vitro, in silico or clinical data, so their synthesis maps reported mechanisms and identifies translational gaps rather than testing therapeutic benefit.

Evidence summarized across the cell envelope shows several routes of antibacterial action. Quercetin, a flavonoid found in A. indica, has been reported to interact with the peptidoglycan layer, increase permeability and damage the wall in laboratory studies. Tannins can form complexes with cell-wall proteins and interfere with adhesins, enzymes and envelope transport systems. Neem constituents including azadirachtin, salannin, meliantriol, mahmoodin and nimbin have also been reported to interfere with cell-wall or membrane synthesis in vitro. In Calotropis procera, flavonoids appear to bind wall and membrane components, while eugenol from O. sanctum alters membrane permeability, allows intracellular material to leak and inhibits membrane ATPase. Saponins can insert into lipid bilayers and disorder membrane lipids, and phenolic acids may interact with both the polar surface and the hydrophobic interior of the membrane.

Other constituents target enzymes required for bacterial survival and replication. In vitro findings summarized in the review indicate that azadirachtin and quercetin inhibit DNA gyrase and its ATPase activity. Docking studies attribute the activity of luteolin from Bacopa monnieri to high affinity for a gyrase-binding site, while phenolic compounds are reported to interfere with dihydrofolate reductase, gyrase B and topoisomerase IV. A compound identified in A. indica as O-geranyl β-D-mannofuranoside was reported in combined in silico and laboratory work to bind penicillin-binding proteins PBP2X and PBP4, as well as tyrosyl-tRNA synthetase and DNA gyrase. Such results indicate multiple possible points of action, but molecular docking and in vitro exposure do not demonstrate that a compound will reach an infection site at an effective concentration in a person.

Perhaps the most relevant mechanism for an adjuvant role is direct interference with bacterial resistance systems. Rutin, a flavonoid associated with C. procera, has been reported in computational and in vitro studies to inhibit beta-lactamases and efflux pumps while reducing biofilm formation. In Klebsiella pneumoniae, it reportedly downregulated about 15 genes associated with biofilm formation. Rutin hydrate had minimum inhibitory concentrations of 128–1,024 micrograms per millilitre across tested strains and produced a fractional inhibitory concentration index below 0.5 when combined with amikacin against four strains, a result classified as synergy. Separately, quercetin inhibited beta-lactamase in amoxicillin-resistant Staphylococcus epidermidis and restored susceptibility, with a fractional inhibitory concentration index of 0.5. These are laboratory interaction results, not evidence that either phytochemical is ready for clinical use.

Biofilms offer a second reason for exploring these compounds as adjuncts. These multicellular aggregates are enclosed in a self-produced extracellular matrix that limits drug penetration, supports horizontal gene transfer and can shelter metabolically dormant persister cells. Biofilms also favor quorum-sensing communication, specialized efflux and the exchange of resistance genes among neighboring bacteria. Several plant constituents act on those processes. Catechin from A. indica was reported to degrade the extracellular polymeric substances that bind a biofilm together and to reduce quorum sensing by 94.56% plus or minus 2.56% in Porphyromonas gingivalis through reduced LuxS activity. Quercetin reduced S. epidermidis biofilm formation at concentrations of 125–1,000 micrograms per millilitre by lowering intercellular-adhesion gene expression and polysaccharide-intercellular-adhesin production. Other evidence reviewed indicates that tannins can inactivate adhesins, while tannin-rich plant fractions inhibit quorum sensing in P. aeruginosa.

The proposed translational strategy is to combine a standardized multi-component plant extract with an existing antibiotic rather than asking the plant material to cure a resistant infection alone. In principle, matrix degradation may improve antibiotic access; inhibition of beta-lactamase may protect a vulnerable antibiotic; and efflux inhibition may increase the intracellular concentration of a drug. Demonstrating that a combination is genuinely synergistic, however, requires more than observing a larger effect than either ingredient produces alone. The review recommends standardized mathematical benchmarks such as Loewe additivity and fractional inhibitory concentration calculations. In the latter method, an index of 1 represents additivity, a value below 1 indicates synergy and a value above 1 indicates antagonism. Time-kill and other common assays can misclassify interactions, so the choice and interpretation of tests are central to the credibility of future results.

Translation is constrained by reproducibility, safety, pharmacokinetics and regulation. Plant composition can vary with season, harvest time and geography, making potency difficult to standardize; analytical methods such as HPLC-ESI-MS/MS can characterize preparations but are slow and costly. Contamination is another documented problem: some commercial preparations have been reported to contain lead, mercury or arsenic at 100–10,000 times recommended limits, while some traditionally processed metal-containing formulations have been associated with elevated human exposure. Herbal medicines are not inherently safe, either, because of adulteration, misidentification, intrinsic plant toxicity, overdose or interactions with conventional drugs. Polyphenols can interfere with iron uptake, digestive enzymes and cytochrome P450 enzymes, which may alter the metabolism of co-administered medicines.

The concentrations that look effective in laboratory assays also raise a major delivery problem. Rutin hydrate at 128–1,024 micrograms per millilitre and quercetin at 125–1,000 micrograms per millilitre reflect direct exposure of cultured bacteria, not concentrations demonstrated in human plasma or infected tissue. Many phytochemicals are poorly soluble, enzymatically degraded, rapidly metabolized or unable to cross biological barriers, including the gastrointestinal tract, endothelial linings and blood-brain barrier. Liposomes, solid lipid nanoparticles and nanostructured lipid carriers are being investigated as ways to improve stability, absorption, dispersion and targeted delivery, but the review reports no new demonstration of clinical performance for these systems. Regulation presents an additional mismatch because most approval frameworks are designed around a single defined active ingredient, while a botanical extract may contain many constituents whose relative concentrations vary with source and processing.

Clinical evidence remains limited. The review notes that most studies supporting the multi-target mechanisms are in vitro, in silico or otherwise preclinical, and that relatively few herbal products have progressed through controlled human trials. Pelargonium sidoides is cited as an established example with clinical evidence for respiratory illnesses, but it does not establish the clinical efficacy of the antimicrobial adjuvants discussed here. The review itself contributes no new experiments, human data or direct test of a phytochemical–antibiotic combination. Its most supportable conclusion is therefore a research proposition: standardized Ayurvedic-derived mixtures merit formal evaluation as antibiotic adjuncts and anti-biofilm agents, with defined compositions, rigorous interaction testing, safety assessment, pharmacokinetic measurement and appropriately designed clinical trials. Until those steps are completed, the evidence supports biological plausibility and a clear testing strategy, not readiness to treat resistant infections with herbal products or to replace existing antibiotics.

Subject of Research: Preclinical review of Ayurvedic phytochemicals as multi-target antibiotic adjuncts against antimicrobial resistance

Article Title: Rethinking Ayurvedic antibacterials: a mechanistic case for multi-target phytochemicals as adjuvants against antimicrobial resistance

Article References: Narayanan KN, H., & Panchapakesan, S. S. S. (2026). Rethinking Ayurvedic antibacterials: a mechanistic case for multi-target phytochemicals as adjuvants against antimicrobial resistance. Frontiers in Pharmacology, 17, Article 1946531. https://doi.org/10.3389/fphar.2026.1946531

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1946531

Keywords: antimicrobial resistance, Ayurvedic medicine, phytochemicals, antibiotic adjuvants, biofilms, polypharmacology, beta-lactamase, efflux pumps, quorum sensing, drug development, Rethinking, Ayurvedic

The research, published in Frontiers in Medicine, followed 963 episodes of complicated urinary tract infection caused by Enterobacterales, the family of gut bacteria that includes Escherichia coli and Klebsiella pneumoniae. Between March 2024 and March 2026, the team at Misurata University and four local hospitals collected 1,017 bacterial isolates in real time, identified them with biochemical panels and MALDI-TOF mass spectrometry, and subjected each to a battery of phenotypic tests for beta-lactamase enzymes and biofilm formation. It is one of the most detailed clinical-microbiological datasets yet assembled from a North African setting that is chronically underrepresented in the infection literature.

The resistance burden they documented is sobering in its own right. More than half of the isolates qualified as multidrug-resistant. Roughly 37 percent produced extended-spectrum beta-lactamases (ESBLs), enzymes that disable penicillins and most cephalosporins. About 18 percent carried AmpC-type enzymes, concentrated in species such as Enterobacter cloacae and Citrobacter freundii, and around one in ten produced carbapenemases, the enzymes that undermine the last-line carbapenem antibiotics. Biofilm formation — the ability to coat surfaces in a protective matrix — was detected in 72 percent of isolates. On paper, these bacteria look formidable.

Yet when the researchers ran the numbers, phenotype after phenotype fell away. In a multivariable logistic regression adjusted for age, sex, hospital, catheterization, prior antibiotics, comorbidities and more, isolates producing two or more beta-lactamase categories showed no significant independent association with treatment failure. Multidrug resistance itself was likewise not independently linked to failure. The adjusted odds ratios hovered near or below one, with confidence intervals that straddled the null in most sensitivity analyses.

What did matter were three clinical factors. Urinary obstruction raised the odds of failure by about 55 percent, diabetes by roughly 48 percent, and sepsis by nearly 60 percent. A separate model examining source control — the surgical or procedural correction of the underlying problem, such as draining an obstructed kidney or swapping an infected catheter — found that when source control was needed but inadequate, the odds of failure roughly doubled compared with cases needing no intervention. The message is physiologically coherent: antibiotics cannot sterilize a plumbing system that remains blocked, and a septic patient has far less reserve to tolerate any delay.

One result was genuinely unexpected. Biofilm-positive infections appeared to fare slightly better, with an adjusted odds ratio of 0.70 in the primary model — an inverse association that seems to contradict decades of laboratory work linking biofilms to persistence and antibiotic tolerance. The authors are emphatic that this should not be read as biofilm being protective. The finding flickered in and out of statistical significance across sensitivity analyses and vanished entirely when the outcome definition was changed, suggesting it is an artifact of confounding, species composition, or how outcomes were measured rather than a real biological effect.

That fragility connects to one of the study’s most instructive methodological episodes. Before modeling, the team cross-checked their locked outcome file against a prespecified rule and found that 36 episodes with documented persistence of the same organism on repeat culture had been coded as successes. Correcting these records lifted the failure count from 152 to 188, or 19.5 percent of episodes. But because repeat urine cultures were obtained only when clinicians felt they were warranted — and were far more common in patients who were doing badly — the opportunity to detect persistence was unevenly distributed across the cohort. This differential verification, the authors acknowledge, could have distorted the very microbiological associations they set out to test.

The study’s statistical honesty is also worth noting. The regression model, after bootstrap correction for optimism, achieved an area under the curve of just 0.575 — barely better than a coin flip for individual prediction. The authors explicitly state the model was built to estimate associations, not to serve as a bedside prognostic tool. In an era when machine-learning models are routinely oversold, this kind of transparent self-assessment is a quiet corrective.

The findings echo a multicenter European study from 2019, in which treatment failure among hospitalized patients with complicated urinary tract infection was likewise driven mainly by markers of host vulnerability — intensive care admission, septic shock, catheter-associated infection — rather than by inappropriate initial antibiotics. Two cohorts, two continents, same pattern: the terrain matters more than the invader’s armaments.

None of this lets antimicrobial resistance off the hook. Resistant bacteria constrain which drugs can be used, how quickly effective therapy can start, and how complex definitive treatment becomes — and in a setting like Misurata, where over half of urinary isolates are multidrug-resistant, those constraints are daily realities. But the study suggests that resistance phenotype is best understood as one input into a broader clinical pathway, not a standalone verdict. For clinicians, the practical takeaway is concrete: in complicated urinary infection, look first for the blocked kidney, the uncontrolled diabetes, the early sepsis, and the drainage that has not happened. Fixing the plumbing, the data imply, may save more treatments than any new antibiotic.

Subject of Research: Clinical and microbiological determinants of treatment failure in complicated urinary tract infection caused by Enterobacterales

Article Title: Clinical and microbiological determinants of treatment failure in complicated urinary tract infection: a four-hospital cohort of enterobacterales infections in Misurata, Libya

Article References: Alwashaish, M. M., Ashour, A. O., Elwash, M. E., & Elmeheishi, F. M. (2026). Clinical and microbiological determinants of treatment failure in complicated urinary tract infection: a four-hospital cohort of enterobacterales infections in Misurata, Libya. Frontiers in Medicine, 13, Article 2002811. https://doi.org/10.3389/fmed.2026.2002811

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.2002811

Keywords: complicated urinary tract infection, Enterobacterales, antimicrobial resistance, beta-lactamase, ESBL, biofilm, treatment failure, sepsis, diabetes, urinary obstruction, Libya, MALDI-TOF

The central idea is elegantly simple. Bacterial cell surfaces are studded with free primary amines, found at the N-termini of surface proteins and in lysine side chains, which are abundant across microbial taxa. The researchers exploited these native chemical handles using a hetero-bifunctional crosslinker called DBCO–sulfo–NHS. One end of this molecule, the sulfo-NHS ester, reacts with the surface amines under biocompatible aqueous conditions. The other end, a dibenzocyclooctyne group, remains available for a strain-promoted azide-alkyne cycloaddition, a bioorthogonal click reaction that specifically couples any molecule bearing an azide tag. This two-step design decouples the species-specific optimization of the surface reaction from the choice of the added functionality, meaning a single standardized protocol can be paired with fluorophores, enzymes, nucleic acids, or potentially any azide-containing compound.

The sulfo group on the NHS moiety proved critical. By enhancing the hydrophilicity of the crosslinker, it eliminated the need for organic solvents and reduced cellular internalization, both of which helped preserve cell viability. The team validated the approach on Escherichia coli, treating cells with a range of crosslinker concentrations from zero to 1000 milligrams per liter followed by an azide-modified Alexa Fluor 488 dye. Confocal microscopy showed bright, uniform surface fluorescence in fully treated cells, while controls lacking either the linker or the fluorophore showed no background signal, confirming that the reaction was specific rather than a product of nonspecific binding or autofluorescence.

Quantifying the trade-off between modification efficiency and cell survival was a key part of the study. Using flow cytometry alongside calibration curves built from fluorescent beads, the researchers converted fluorescence measurements into absolute numbers of molecules per cell. At the highest crosslinker concentration, roughly 210,000 molecules were tethered to each E. coli cell, corresponding to a surface density of about one molecule every 30 square nanometers, or a mean spacing of roughly five nanometers between adjacent molecules. Importantly, viability measured with the dead-cell stain SytoX Orange remained at 91 percent, and growth rates were indistinguishable from untreated controls. Only at extreme concentrations did cell death begin to rise, and even then the effect was modest.

Recognizing that membrane integrity alone does not capture the full picture of cellular health, the team also introduced a new standardized assay they call the regrowth dynamics assay. Rather than simply counting stained cells or colony-forming units, the method tracks the optical density of treated cultures over time, fits the curves to exponential or logistic growth models, and estimates the initial active population. Because cells that survive but lag in regrowth contribute less to the estimate, the assay is more stringent than conventional viability measures. Reassuringly, the regrowth-based estimates closely matched the dye-based ones, with 88 percent viability at the highest crosslinker dose, and neither method detected a significant departure from full viability at working concentrations.

To test universality, the researchers applied the protocol to five additional taxonomically diverse isolates: two aerobic marine Gram-negative strains, Vibrio splendidus and Neptunomonas sp.; the anaerobic gut bacterium Bacteroides ovatus; and two Gram-positive probiotic species from human stool, Lactococcus lactis and Lactobacillus rhamnosus. The anaerobic strains were functionalized under anaerobic conditions. Across all six organisms, the method tethered between 60,000 and 250,000 molecules per cell without significant viability losses or growth-rate changes. Gram-positive strains took up more molecules at a given crosslinker concentration but were also more sensitive to the treatment, a pattern the authors say reflects the distinct surface architectures of the two groups. Benchmarking against prior techniques made the advantages stark: metabolic labeling achieved at most a tenfold fluorescence increase compared with the 110-fold increase seen here, periodate-based oxidation dropped E. coli viability below 0.01 percent, and established biotin–sulfo–NHS protocols attached fewer than 4,000 molecules per cell versus 210,000 with the new crosslinker.

The practical power of the technique became clear in three demonstrations. First, cells coated with azide-modified beta-lactamase enzymes gained striking antibiotic resistance. In minimum inhibitory concentration assays, cells functionalized with 40 micromolar enzyme showed more than a 200-fold increase in ampicillin tolerance relative to untreated controls, with the effect scaling with enzyme dose. Even more striking, surface-bound enzymes outperformed the same enzymes free in solution, achieving equal or greater protection with tenfold fewer enzyme molecules. This spatial localization effect suggests that tethering catalytic machinery directly to the cell surface is a fundamentally efficient way to extend a microbe’s biochemical repertoire, with obvious implications for engineered probiotics that could survive antibiotic co-treatment.

Second, and perhaps most visually dramatic, the team used the method to program cell-to-cell adhesion with single-stranded DNA. Two populations of E. coli, each coated with a different 20-nucleotide azide-modified sequence, were mixed together. Complementary strands hybridized on contact, driving the cells to self-assemble into macroscopic aggregates visible within an hour. By fitting the sedimentation kinetics to a simplified aggregation model, the researchers calculated adhesion probabilities per cell encounter, which rose from a background of 0.2 percent to fifteen times that level at the highest DNA density. Non-complementary DNA controls showed no aggregation, confirming sequence specificity. Confocal imaging of red- and green-fluorescent populations revealed highly mixed aggregates, with 78 percent of nearest-neighbor pairs consisting of opposite-colored cells, well above the 50 percent expected from random assortment. Embedded in nutrient agar, the aggregates continued to grow, with cells dividing uniformly throughout the clusters.

The implications reach across biotechnology, medicine, and environmental engineering. Antibiotic-resistant probiotics could help maintain gut diversity during antibiotic treatment, a period when patients are vulnerable to infections such as Clostridioides difficile. Structured, DNA-programmed consortia could serve as seeding communities for microbiome modulation, biofilm engineering, and bioremediation, where spatially organized communities have been shown to remove pollutants more effectively. Because the method is purely chemical, it sidesteps the regulatory and ecological concerns surrounding genetically modified organisms, and it works on species that remain genetically intractable.

The approach does have limits. Some empirical optimization is still needed for each new species, since crosslinker sensitivity varied considerably between strains, and because nothing is genetically encoded, the modifications are temporary. Fluorescence measurements of dividing lineages showed that surface molecules are diluted by half with each cell division, so the longevity of any engineered phenotype depends on the cell’s growth rate and the density of molecules required for the function in question. Even so, the authors argue that the platform establishes a simple yet powerful framework for microbial surface engineering, one that decouples functional enhancement from genetic and metabolic constraints and opens the door to next-generation live therapeutics and synthetic microbial communities with capabilities their genomes never encoded.

Subject of Research: A universal chemical surface functionalization method for live microbial cells using hetero-bifunctional DBCO–sulfo–NHS crosslinkers

Article Title: A universal surface functionalization technique to chemically enhance live microbial cells

Article References: Vercelli, G. T., Zhou, X., Moreno-Gámez, S., Jeeda, R. R., Gregor, R., Słomka, J., Dagadu, A., Furst, A. L., & Cordero, O. X. (2026). A universal surface functionalization technique to chemically enhance live microbial cells. Molecular Systems Biology, 22(6), 962-978. https://doi.org/10.1038/s44320-026-00202-z

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00202-z

Keywords: surface functionalization, bacteria, click chemistry, DBCO, SPAAC, beta-lactamase, antibiotic resistance, DNA hybridization, cell adhesion, probiotics, synthetic biology, non-genetic engineering

The synthetic route itself is elegantly simple. Substituted aromatic aldehydes, methyl cyanoacetate and barbituric acid are combined in a 1:1 mixture of ethanol and water at 85 degrees Celsius with just 0.03 mol percent of Bi(OTf)3. The catalyst orchestrates a domino Knoevenagel-Michael sequence: it coordinates to the ester oxygen of methyl cyanoacetate, sharpening the electrophilicity of the carbonyl carbon, while the aldehyde-derived enolate attacks to form a carbon-carbon bond. The resulting alpha,beta-unsaturated intermediate is then struck by the weakly nucleophilic nitrogen of barbituric acid, and intramolecular cyclization closes the fused pyridopyrimidine ring. Eight derivatives, bearing nitro, bromo, hydroxyl, methyl, methoxy or unsubstituted phenyl groups, were isolated in yields ranging from 76 to 91 percent within two to five hours, with minimal side products and no need to purify intermediates.

What makes the protocol genuinely green is the solvent system and the catalyst. Bismuth(III) salts have gained a reputation as environmentally benign alternatives to conventional Lewis acids because they are air- and moisture-stable, functionally tolerant, commercially available and far less corrosive than many metal halides. Compared with earlier methods, the advantages are clear. A DMAP-catalyzed protocol requires ultrasonic irradiation in toxic DMF, ZrO2 nanoparticles demand nanomaterial synthesis and raise agglomeration concerns, and the sulfonated SBA-15 catalyst involves a cumbersome multistep preparation. The bismuth route runs in a drinkable solvent mixture under ordinary reflux, and the catalyst can be recovered, although reusability tests showed a gradual decline: the model reaction yielded 79 percent in the first cycle, 74 percent in the second, 65 percent in the third and only 33 percent in a fourth run that stretched to nine hours. The authors suggest that immobilization strategies could extend catalyst lifetime in future work.

On the computational side, the team optimized all eight molecules at the B3LYP/6-31G(d,p) level of density functional theory, confirming that each geometry corresponds to a true energy minimum. Frontier molecular orbital analysis revealed that the nitro-substituted compounds 4a and 4b possess the smallest HOMO-LUMO gaps, at roughly 0.135 electron volts, making them the most electronically soft and reactive members of the series, primed for donor-acceptor interactions with biological macromolecules. In contrast, the bromo, methyl and unsubstituted derivatives 4c, 4f and 4g showed the largest gaps and the greatest hardness, indicating higher kinetic stability. Mulliken charge analysis and molecular electrostatic potential maps pinpointed the carbonyl oxygens and ring nitrogens as the electron-rich hotspots most likely to engage in hydrogen bonding with protein targets, while the N-H hydrogens carried the complementary positive charge.

The biological evaluation used the broth dilution method to determine minimum inhibitory concentrations against four bacterial strains, the Gram-negative Escherichia coli and Pseudomonas aeruginosa and the Gram-positive Staphylococcus aureus and Streptococcus pyogenes, benchmarked against ampicillin, and three fungal strains, Candida albicans, Aspergillus niger and Aspergillus clavatus, benchmarked against griseofulvin. The structure-activity trends were striking. The unsubstituted compound 4g and the methoxy-bearing 4h were the standout antibacterial agents, with MIC values as low as 65 and 62 micrograms per milliliter respectively against E. coli and S. aureus, figures that actually beat ampicillin on those strains. The methyl derivative 4f was the most potent antifungal, matching griseofulvin’s 100 micrograms per milliliter against A. niger. Electron-donating groups such as methyl and methoxy generally enhanced activity, likely by improving lipophilicity and membrane penetration, while nitro groups tended to raise MIC values.

To explain these observations mechanistically, the researchers docked all eight compounds into two clinically significant enzymes: bacterial beta-lactamase, the molecular engine of antibiotic resistance, and sterol 14-alpha demethylase CYP51, the fungal enzyme that builds ergosterol membranes. Using AutoDock 4.2 with a Lamarckian genetic algorithm, they found that compounds 4b and 4h bound beta-lactamase most favorably, with estimated free energies of binding of minus 9.30 and minus 9.43 kilocalories per mole, stabilized by networks of hydrogen bonds, pi-alkyl contacts and pi-cation interactions with residues such as ARG 661, PRO 298 and TYR 611. Against CYP51, compound 4b again led with minus 7.79 kilocalories per mole, and the methyl-substituted 4f formed six hydrogen bonds within the active site, consistent with its antifungal potency. Torsional free energies were nearly uniform across the series, indicating that differences in affinity stem from noncovalent interaction networks rather than ligand flexibility.

Molecular dynamics simulations then stress-tested the most promising complexes over 100-nanosecond production runs using the Maestro-Desmond package with the OPLS3e force field. The 4f-beta-lactamase complex held a backbone root mean square deviation averaging 1.60 angstroms, comfortably below the 2.0 angstrom threshold that validates docking reliability, and stabilized after an initial 30-nanosecond equilibration. The 4d-CYP51 complex averaged 1.40 angstroms, closely tracking the reference antifungal ligand VT1 at 1.35 angstroms. Root mean square fluctuation analysis showed that flexibility was confined to loop and terminal regions, leaving the binding pockets rigid. Contact histograms revealed that water-bridged hydrogen bonds, involving residues such as Ser64, Gln120, Thr122 and Tyr132, together with hydrophobic contacts, were the main glue holding the complexes together throughout the simulations.

The pharmacoinformatic layer of the study added yet another dimension. POM analysis, which classifies bioactivity based on dipolar interactions between electron-rich and electron-deficient centers, identified three distinct antitumor pharmacophore regions built from NH donor to carbonyl oxygen acceptor pairs, plus a single antibacterial pharmacophore involving an NH-CO motif. OSIRIS toxicity screening found no major mutagenic, tumorigenic, irritant or reproductive risks across the series, with compounds 4d and 4g earning the highest drug scores at 0.70 and 0.87. Molinspiration calculations confirmed that all eight molecules respect Lipinski’s criteria almost entirely: molecular weights below 500 daltons, five or fewer rotatable bonds, moderate polarity and acceptable lipophilicity, with only the heavily nitrated pair showing a single violation.

Taken together, the work demonstrates a rare degree of coherence between experiment and computation. The compounds with the best MIC values, notably 4f, 4g and 4h, also posted strong docking energies and stable dynamic behavior, while the electrostatic potential maps independently flagged the same carbonyl and ring nitrogen atoms that docking identified as interaction points. The authors conclude that pyrido[2,3-d]pyrimidines represent a promising scaffold for further antimicrobial development, and that targeted substitution of the aromatic ring is the key lever for tuning activity. With antimicrobial resistance declared one of the top global public health threats, a synthetic method that is cheap, green and high-yielding, paired with a validated computational pipeline for prioritizing candidates, offers exactly the kind of integrated approach the field has been calling for. The next step will be translating these laboratory and in silico hits into lead compounds capable of surviving the far harsher tests of animal models and, eventually, the clinic.

Subject of Research: Green synthesis and antimicrobial evaluation of pyrido[2,3-d]pyrimidine derivatives catalyzed by bismuth(III) triflate

Article Title: Bi(OTf)₃-catalyzed one-pot synthesis and antimicrobial evaluation of bioactive pyridopyrimidines supported by DFT, molecular dynamics, POM and pharmacophore analyses

Article References: Mehta, A. W., Abdel-Megid, M., Patil, R. C., Ahmed, S., Salem, M. E., Abu-Rayyan, A., Shtaiwi, A., Hajam, Y. A., Bhat, A. R., Eissa, M. E., Agisho, H. A., Mujahid, M. H., Yamari, I., Raza, N., & Zbancioc, A. M. (2026). Bi(OTf)₃-catalyzed one-pot synthesis and antimicrobial evaluation of bioactive pyridopyrimidines supported by DFT, molecular dynamics, POM and pharmacophore analyses. Results in Chemistry, 30, Article 103849. https://doi.org/10.1016/j.rechem.2026.103849

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103849

Keywords: pyridopyrimidines, bismuth(III) triflate, multicomponent reaction, green chemistry, antimicrobial activity, molecular docking, molecular dynamics, DFT, beta-lactamase, CYP51, drug discovery, pharmacophore

The World Health Organization ranks antimicrobial resistance among the leading global health challenges, and the stakes of getting this science right could hardly be higher. When resistance is misjudged, antibiotics fail in the clinic, infections spread, and the pipeline of effective drugs narrows further. The new opinion piece, authored by Professor Frank Møller Aarestrup of the DTU National Food Institute and colleagues including Professor Thomas Bjarnsholt of the University of Copenhagen and Copenhagen University Hospital, draws on recent experimental findings suggesting that factors such as temperature, oxygen availability, and pH can determine whether a bacterium carrying a resistance gene actually behaves in a resistant manner.

Two underlying studies anchor the argument. One examined how the contrasting pH optima of the beta-lactamase enzymes CTX-M and CMY influence the fitness and resistance ecology of Escherichia coli. The other showed that environmental factors, specifically pH and redox potential, modulate beta-lactamase phenotypes and thereby alter beta-lactam resistance. Together, these findings indicate that the expression of resistance is not an intrinsic, unvarying trait encoded neatly in a gene, but a phenotype that depends on the microenvironment in which the bacterium finds itself at a given moment.

According to Aarestrup, this realization demands that researchers ask a far more granular set of questions. Is a bacterium carrying a resistance gene resistant at a pH of 5 or 8, when standard laboratory testing is performed at a fixed pH of 7.2? What oxygen levels and temperatures permit resistance to manifest? Does a patient’s fever change the answer? Is the bacterium residing in the oxygen-poor environment of the gut or in the oxygenated bloodstream? Current diagnostic protocols, he notes, take none of these biological conditions into account, even though they are precisely the conditions a bacterium encounters inside the human body.

Bjarnsholt frames the conceptual shift in equally stark terms. Resistance genes, he emphasizes, do not function in a vacuum. They exist in different bacterial species and in varying microenvironments, and the scientific community must therefore stop asking only which resistance genes a bacterium possesses and start asking when those genes actually render the bacterium resistant. The distinction is more than semantic. It implies that a bacterium classified as resistant in a standardized assay could behave as fully susceptible in the tissue of a patient, and vice versa, potentially explaining the frustrating clinical scenarios in which a course of antibiotics fails despite a laboratory report predicting success, or succeeds when the laboratory predicted failure.

The researchers acknowledge that embracing this context-dependent view of resistance will make laboratory measurement considerably harder. For decades, enormous effort has gone into standardizing susceptibility testing worldwide, so that a result produced in Copenhagen can be compared with one produced in Nairobi or São Paulo. Measuring resistance across a matrix of pH values, oxygen concentrations, temperatures, and host conditions multiplies the experimental burden many times over. Yet the researchers contend that the payoff justifies the effort, because a richer dataset would capture the true behavior of resistance genes under the conditions that matter in real infections.

Perhaps the most provocative implication concerns treatment strategy. If resistance manifests only when certain conditions are met, then it may become possible to select antibiotics that trigger the development of resistance only under circumstances that never occur in the human body, for example at a temperature far above physiological norms. Such a strategy would, in principle, allow clinicians to treat infections while deliberately choosing drugs whose resistance pathways remain switched off in the patient. Aarestrup suggests that this line of thinking could open entirely new approaches to combating resistance in humans, animals, and the wider environment, moving beyond the current reactive cycle of drug use followed by resistance emergence.

The environmental dimension of the proposal is equally significant. Resistance genes circulate through soil, water, wastewater, and animal populations, and monitoring efforts have long struggled to interpret what the presence of a gene in these reservoirs actually means for human health. If gene presence no longer equates to functional resistance, environmental surveillance could be refined to identify the conditions under which environmental resistance genes become clinically relevant, offering a better chance of intervening before dangerous resistance traits migrate into human pathogens. More targeted treatment of animals could similarly reduce the selective pressure that farms currently exert on bacterial communities.

Realizing this vision will require an enormous collective undertaking. The researchers argue that large volumes of new data on resistance across a range of biological conditions must be collected, effectively restarting resistance gene research from square one. Aarestrup envisions grouping resistance genes into categories and then deploying computational models and artificial intelligence to identify the relationships between genes and varying conditions, a task well suited to machine learning given the combinatorial complexity of gene-by-environment interactions. Such an effort would revisit and reassess much of the knowledge accumulated over decades of research built on the old binary model.

The opinion piece, titled From resistance genes to resistance states and enzymatic context-dependence in antimicrobial resistance, was published on 16 September 2026 and declares no competing interests. Whether the field adopts the proposed framework will depend on whether laboratories, regulators, and diagnostic manufacturers are willing to abandon a century of standardized practice in favor of a messier but potentially far more accurate picture of microbial behavior. If the Danish team is right, the future of antibiotic stewardship may lie not in discovering new drugs alone, but in understanding precisely when, where, and under what conditions the drugs already in use lose their power, and in engineering treatment strategies that keep resistance from ever switching on.

Subject of Research: Context-dependent antibiotic resistance and the environmental conditions that determine whether resistance genes make bacteria resistant

Article Title: Researchers in Denmark aim to find new solutions in the fight against antibiotic resistance

Article References: Researchers in Denmark aim to find new solutions in the fight against antibiotic resistance. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: antibiotic resistance, antimicrobial resistance, Trends in Microbiology, Technical University of Denmark, beta-lactamase, pH, microenvironment, diagnostics, Escherichia coli, resistance genes, public health, WHO

Pseudomonas aeruginosa is one of medicine’s most formidable opponents. This Gram-negative bacterium accounts for roughly ten to eleven percent of all hospital-acquired infections and can strike the lungs, bloodstream, urinary tract, eyes, and skin, with particular menace for immunocompromised patients. It belongs to the notorious ESKAPE group of pathogens and resists treatment through multiple overlapping strategies: enzymes that destroy antibiotics, altered drug targets, reduced membrane permeability, active efflux pumps, and protective biofilms. The World Health Organization has designated it a priority pathogen, and recent surveillance has documented a steady rise in carbapenem-resistant strains between 2014 and 2024, driven by the organism’s remarkable genetic plasticity and its propensity for horizontal gene transfer.

The core problem the researchers set out to address is a diagnostic blind spot. Traditional phenotypic susceptibility testing, whether by disk diffusion or automated systems, measures what a bacterium does under laboratory conditions, not what it is genetically capable of doing. Molecular panels, meanwhile, only look for pre-established markers and can miss novel or situation-specific determinants. Phenotype-based approaches are slow and open to interpretation, while targeted molecular methods are costly and limited in scope. Neither reliably detects silent resistance determinants or early adaptive changes, which means a patient’s infection may appear treatable on paper while the underlying genome tells a more troubling story.

The investigation began with 1,295 culture-positive Pseudomonas aeruginosa specimens collected at the Central Laboratory of IMS and SUM Hospital in Odisha between January 2023 and December 2024. All isolates underwent antimicrobial susceptibility testing using both the Kirby-Bauer disk diffusion method and the VITEK-2 automated system, following CLSI and EUCAST standards. Multidrug resistance was defined using the internationally recognized Magiorakos criteria. To select representative strains for deep sequencing, the team applied principal component analysis and hierarchical clustering across twelve antibiotics, calculating a resistance burden score for each isolate. From this landscape they chose three isolates spanning the spectrum: two multidrug-resistant strains, designated 0040 and 1609, and one largely susceptible non-MDR isolate, 0727, drawn from diverse specimen sources including urine, pus, and tracheal aspirates, and from both hospital- and community-acquired settings.

Species identity was confirmed by 16S rRNA sequencing, and genomic DNA was sequenced on an Illumina NovaSeq platform using paired-end reads. After quality trimming with Trimmomatic, cleaned reads were mapped to the well-characterized PA14 reference genome with BWA-MEM, achieving greater than 92 percent coverage at 30-fold depth for all three isolates. Variant calling with the GATK HaplotypeCaller applied deliberately stringent filters, retaining only high-confidence homozygous alternate variants with perfect allele frequency, and SnpEff annotated the functional consequences. Notably, none of the isolates carried loss-of-function mutations in the mismatch repair genes mutS, mutL, or uvrD, ruling out a hypermutator state and indicating that the elevated variant loads reflected deep lineage divergence rather than runaway mutation. Resistance genes were identified against the Comprehensive Antibiotic Resistance Database using strict confidence thresholds that admitted only perfect and strict hits.

The genomic arithmetic told a striking story. The multidrug-resistant isolates diverged from PA14 by approximately 69,000 variants, compared with roughly 58,700 for the non-MDR strain, indicating substantial evolutionary separation despite superficially similar phenotypes among the resistant pair. In the MDR isolates, genotype and phenotype agreed closely across five antibiotic classes. Their resistance was anchored by beta-lactamase variants PDC-67 and OXA-396, chromosomal enzymes that become dangerous when regulatory adaptations amplify their output. Crucially, the team detected variants in the regulatory elements ArmR and cprS, which are known to drive overexpression of these beta-lactamases, providing a coherent mechanistic explanation for the observed multidrug resistance.

The non-MDR isolate 0727 told a very different and more unsettling tale. Despite being susceptible to most antibiotic classes in phenotypic testing, it carried a gyrA T83I mutation, a well-known fluoroquinolone resistance-associated change, along with the PDC-1 and OXA-847 beta-lactamase variants. None of these determinants were expressed as measurable resistance. The pattern constitutes what the researchers call a silent resistome: resistance genes present and intact but transcriptionally dormant or functionally masked, perhaps awaiting regulatory shifts, efflux upregulation, or stress-mediated induction to switch on. Similar genotype-phenotype discordance has been documented in Shigella and in Gram-negative uropathogens, reinforcing the emerging consensus that gene presence alone does not equal resistance, and that quinolone resistance in particular typically requires synergistic factors beyond single point mutations.

To place these clinical isolates in global context, the team constructed a phylogenetic tree from 454 genomes, combining their three isolates, the PA14 reference, and 450 publicly available assemblies selected for quality and recency. Pairwise distances computed with Mash revealed that the two MDR isolates clustered tightly in a single clade with short terminal branches, indicating recent common ancestry and minimal divergence between them, embedded among publicly available clinical genomes. The closest neighbor to this pair was a 2021 clinical isolate from South Korea. In contrast, isolate 0727 occupied a distinct terminal branch in a separate clade, grouping most closely with diverse lineages that included a 2007 cystic fibrosis isolate from Denmark, a pattern consistent with weaker antibiotic selection and greater phylogenetic spread among susceptible strains. The findings echo prior work showing that hospital-derived resistant strains often form compact phylogenetic groups under shared selective pressure, raising the possibility of common transmission pathways that would require formal epidemiological tracing to confirm.

The study also surfaced an intriguing metabolic signal. The MDR isolates produced only diffuse fluorescent green pigmentation in broth culture, while the non-MDR strain displayed a stronger greenish-blue pigment gradient, differences the authors link cautiously to the metabolic cost of sustaining resistance. Maintaining efflux pumps and drug-destroying enzymes is energetically expensive, and previous research has shown that multidrug-resistant strains often suppress costly secondary metabolites such as pyocyanin to conserve resources for survival. The authors stress that these pigment observations are visual only and require quantitative biochemical confirmation, but they add a compelling dimension to the picture of resistance as an adaptation with measurable physiological trade-offs.

The clinical implications are sobering. A phenotypically susceptible isolate can carry latent determinants with the theoretical potential to become active under antibiotic pressure, meaning that a seemingly safe treatment choice could, in principle, select for emergence of resistance from within the infecting population. The authors argue that genomic data should be integrated into surveillance alongside phenotypic testing, and they call for transcriptomic studies to reveal how silent resistomes are regulated and when they might be roused. They acknowledge the limitations of sequencing only three isolates from a single institution and emphasize that larger, longitudinally sampled collections with functional validation are needed. Still, their strategy of using multivariate phenotypic screening to select a small, representative subset for whole-genome sequencing offers a practical template for resource-limited settings, where sequencing every isolate remains out of reach. As antimicrobial resistance accelerates worldwide, this study makes clear that what diagnostic labs cannot see in a Petri dish may already be written in the bacterial genome, waiting for its moment.

Beyond the immediate findings, the study illustrates how reference-guided sequencing workflows can be adapted to routine clinical laboratories. By mapping reads against the well-characterized PA14 reference rather than attempting full de novo assembly, the researchers kept computational demands modest while still resolving tens of thousands of variants, an approach that smaller hospital laboratories in low- and middle-income settings could realistically adopt as sequencing costs continue to fall.

The reliance on the Comprehensive Antibiotic Resistance Database also underscores a broader shift in resistance detection. Curated databases with defined confidence levels allow laboratories to distinguish high-confidence resistance determinants from ambiguous hits, reducing the false alarms that have historically plagued in silico resistance prediction. This standardization is becoming increasingly important as genomic surveillance programs expand globally and as public health agencies move toward harmonized interpretation of resistance genotypes.

The phylogenetic placement of the isolates carries practical weight as well. Tight clustering of the multidrug-resistant pair, alongside a clinical isolate from South Korea, fits a pattern increasingly documented worldwide in which resistant hospital strains spread across borders through patient movement, medical tourism, or shared equipment lineages. Distinguishing such imported or transmitted clones from locally evolved ones is central to infection control, and the Mash-based distance approach used here offers a rapid screen for that purpose.

Finally, the silent resistome concept reframes how susceptibility results should be read. A susceptible report reflects conditions in a growth medium at a single moment, not the full adaptive potential encoded in the genome. As regulatory shifts, efflux changes, or selective pressure during therapy can awaken dormant determinants, longitudinal monitoring of patients and institutional surveillance that pairs phenotypic testing with periodic sequencing may become essential to anticipate resistance before it emerges at the bedside.

Subject of Research: Genotype-phenotype concordance and cryptic resistomes in clinical Pseudomonas aeruginosa characterized by comparative whole-genome sequencing.

Article Title: Comparative genomics reveals genotype-phenotype concordance and cryptic resistomes in clinical Pseudomonas aeruginosa

Article References: Routray, S. P., Swarnkar, T., Subudhi, E., & Panigrahy, R. (2026). Comparative genomics reveals genotype-phenotype concordance and cryptic resistomes in clinical Pseudomonas aeruginosa. International Microbiology. https://doi.org/10.1007/s10123-026-00892-3

Image Credits: AI Generated

DOI: 10.1007/s10123-026-00892-3

Keywords: Pseudomonas aeruginosa, antimicrobial resistance, whole-genome sequencing, multidrug resistance, silent resistome, genotype-phenotype concordance, beta-lactamase, phylogenetics, hospital-acquired infection, genomic surveillance, ESKAPE pathogens, gyrA mutation